The legal action, initiated by the Rosen Law Firm, centers on claims that Embecta defendants disseminated false or misleading information concerning the firm’s fiscal results. Specifically, the complaint alleges that leadership characterized the company's pen needle business as "incredibly resolute" shortly before failing to meet market expectations and subsequently slashing its 2026 fiscal guidance. Investors argue that these actions masked unattainable performance targets, causing financial harm when the reality of the company's position emerged.

Parties interested in participating in the litigation or serving as lead plaintiff must file a motion with the court by the August 17 deadline. While a lawsuit has been filed, no class has been certified, meaning investors are not currently represented by counsel unless they retain their own. Participation in potential future recoveries does not require an investor to serve as a lead plaintiff, though those who choose to take an active role in the litigation can contact Phillip Kim at the Rosen Law Firm for further guidance.